VK2735
VK2735 has been studied in 1 paper since 2025: 1 trial in people; 1 in the past year. The newest paper, Nov 3, 2025: “VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes”.
1 paper studies itUpdated
- 2 trials, none about aging
- 2 of 2 trials sponsored by its developers
- Human trial1
Who is developing VK2735?
1 company: Viking Therapeutics.
- Companies
- Viking TherapeuticsPhase 3
Trial sponsors
Company2 trialsPhase 31,120 people
Latest
1 paper in 12 monthsAHA Scientific Sessions 2025 Abstract
VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
Trial protocolOverweight